鄭彪博士畢業(yè)于浙江大學(xué)醫(yī)學(xué)院醫(yī)學(xué)系；獲上海復(fù)旦大學(xué)醫(yī)學(xué)院免疫學(xué)碩士及倫敦大學(xué) (King’s College, University of London) 免疫學(xué)博士學(xué)位。曾在美國(guó)馬里蘭大學(xué)醫(yī)學(xué)院 (University of Maryland School of Medicine) 及杜克大學(xué)醫(yī)學(xué)中心 (Duke University Medical Center) 任教。隨后任職于美國(guó)貝勒醫(yī)學(xué)院 (Baylor College of Medicine), 為該校病理和免疫系終身教授。在葛蘭索史克 (GlaxoSmithKline) 研發(fā)中心負(fù)責(zé)免疫學(xué)研究工作。曾任美國(guó)強(qiáng)生公司(Janssen Pharmaceuticals, Johnson & Johnson) 全球副總裁, 負(fù)責(zé)亞太地區(qū)免疫領(lǐng)域創(chuàng)新藥物研發(fā)，包括免疫調(diào)節(jié)機(jī)制、腫瘤免疫、及自身免疫性疾病。鄭彪博士現(xiàn)任邦耀生物首席執(zhí)行官。
鄭彪教授學(xué)術(shù)著作豐厚，其中多篇發(fā)表在Nature和Science等世界頂尖雜志上。在馬里蘭大學(xué)、杜克大學(xué)及貝勒醫(yī)學(xué)院工作期間獲得多項(xiàng)重大科研基金，包括美國(guó)NIH科研基金、白血病與淋巴瘤協(xié)會(huì)基金、美國(guó)關(guān)節(jié)炎基金會(huì)、美國(guó)心臟研究協(xié)會(huì)基金、美國(guó)衰老研究聯(lián)盟基金等。在藥物研發(fā)方面，從新藥篩選、靶點(diǎn)研究、疾病模型、臨床前及臨床試驗(yàn)等方面積累了重要的經(jīng)驗(yàn)，對(duì)新藥開(kāi)發(fā)全過(guò)程有深刻的認(rèn)識(shí)。在打造小分子藥，大分子抗體藥，細(xì)胞治療管線均有豐富的經(jīng)驗(yàn)。
Dr. Biao Zheng graduated with a medical degree from Zhejiang University School of Medicine. He received his PhD in Immunology from King’s College, University of London. Dr. Zheng served at the faculty of University of Maryland School of Medicine and Duke University Medical Center. He was a tenured professor in the Department of Pathology and Immunology, Baylor College of Medicine. Dr. Zheng worked for GlaxoSmithKline R&D Center as the head of Immunological Discovery Sciences. He was a global vice president of the Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific, responsible for the innovative immunological drug pipeline in the region. Dr. Zheng is now the Chief Executive Officer at BRL Medicine.
Dr. Zheng is an experienced physician scientist, drug hunter, and professor with a demonstrated history working both in academia and pharmaceutical industry. He has more than thirty years of experience in biomedical research and drug discovery. He has published extensively in world top journals including Nature and Science. His major areas of research and development include autoimmune diseases, immuno-oncology, and novel vaccine development.